Ginkgo Bioworks Holdings, Inc.DNA
What Ginkgo Bioworks Holdings, Inc. does.
Unless the context otherwise requires, all references in this section to the “Company,” “Ginkgo,” “we,” “us,” or “our” refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries.
Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
2. Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $76.7M | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Net income | -$126.6M | -$1.8B | -$2.1B | -$892.9M | -$547.0M | -$312.8M |
| Free cash flow | -$193.7M | -$310.3M | -$304.5M | -$336.3M | -$382.1M | -$178.7M |
More on DNA.
- Ginkgo Bioworks Holdings, Inc. summary
- Ginkgo Bioworks Holdings, Inc. financial statements
- Ginkgo Bioworks Holdings, Inc. key metrics
- Ginkgo Bioworks Holdings, Inc. health scores and style box
- Ginkgo Bioworks Holdings, Inc. earnings
- Ginkgo Bioworks Holdings, Inc. dividends
- Ginkgo Bioworks Holdings, Inc. valuation
- Ginkgo Bioworks Holdings, Inc. ownership and insiders
- Ginkgo Bioworks Holdings, Inc. peers
Figures from Ginkgo Bioworks Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.